MAUNA KEA TECHNOLOGIES (EPA:MKEA) Mauna Kea Technologies: Grenoble University Hospital first hospital in France to set up a multidisciplinary optical biopsy program with the Cellvizio endomicroscopy platform

Transparency directive : regulatory news

31/03/2015 17:45

PRESS RELEASE

       GRENOBLE UNIVERSITY HOSPITAL FIRST HOSPITAL IN FRANCE TO SET UP A
  MULTIDISCIPLINARY OPTICAL BIOPSY PROGRAM WITH THE CELLVIZIO ENDOMICROSCOPY
                                  PLATFORM

  The Grenoble University Hospital has acquired two Cellvizio endomicroscopy
   systems for the gastroenterology, interventional pulmonology and urology
                                 departments

PARIS, March 31, 2015 - Mauna Kea Technologies (Euronext: MKEA, FR0010609263),
inventor of Cellvizio(r), the multidisciplinary confocal laser endomicroscopy
platform, today announced the set-up of an optical biopsy program at the CHU de
Grenoble (university hospital center). The CHU de Grenoble is now the first
hospital in France to offer its gastroenterology, interventional pulmonology and
urology patients a higher standard of care thanks to the endomicroscopy
technology developed by Mauna Kea Technologies.

"We are delighted to be setting up an endomicroscopy program for urology in our
department", commented Professor Jean-Luc Descotes, Head of the Urology and
Renal Transplantation department and Chairman of the French Urology Association
(AFU). "The use of endomicroscopy across multiple areas of urology holds great
promise for improving the treatment of conditions affecting a large number of
patients."

Several clinical and cost/benefit programs will be launched following the
installation of two Cellvizio systems at the Grenoble University Hospital, with
practitioners from several specialties. In Gastroenterology, physicians will
have a strong focus on the treatment of biliary and pancreatic pathologies. In
the field of interventional pulmonology, the hospital will be the first in
France to explore the use of optical biopsy to reduce the risks associated with
physician biopsies in lung transplant patients, following the ground-breaking
work performed at Mayo Clinic in Jacksonville, Florida.

"Our long tradition of innovative patient care is paying off once again with the
set-up of a full optical biopsy program in partnership with a French company",
stated Mrs. Jacqueline Hubert, CEO of the Grenoble University Hospital, "Our
practitioners will be able to harness crucial additional information when making
their therapeutic decisions, which will definitely help to reduce the number of
unnecessary procedures, while providing better options to numerous patients with
digestive, pulmonary and urological conditions".

About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company focused on leading
innovation in endomicroscopy and optical biopsy. The company designs, develops
and markets innovative tools to visualize and detect cell abnormalities in real
time during standard gastrointestinal and pulmonary endoscopy procedures. The
company's flagship product, Cellvizio(r), a probe-based Confocal Laser
Endomicroscopy (pCLE) system, provides physicians and researchers with
high-resolution cellular imaging of internal tissues. Large- scale,
international, multi-center clinical trials have demonstrated Cellvizio's
ability to help physicians to more accurately detect early forms of diseases and
make immediate treatment decisions. Designed to help physicians in their
diagnoses, provide patients with better treatment and reduce hospital costs, the
Cellvizio system can be used with practically all endoscopes. Cellvizio has
510(k) clearance from the United States Food and Drug Administration and CE
Marking in the European Union for use in the gastrointestinal tract and the
urinary and respiratory systems, for endoscopic exploration of the biliary and
pancreatic ducts, and for fine-needle aspiration procedures. Cellvizio also
obtained SFDA regulatory approval in China and MHLW approval in Japan.

For more information on Mauna Kea Technologies, visit www.maunakeatech.com

Mauna Kea Technologies           France and Europe
Eric Cohen                       NewCap
Vice President Finance           Investor Relations & Financial Communication
Tel: +33 (0)1 70 08 09 70        Florent Alba / Pierre Laurent
investor-vpf@maunakeatech.com    Tel: +33 (0)1 44 71 94 94
                                 maunakea@newcap.fr

United States
Berry & Company Public Relations
US - Public Relations
Bill Berry
Tel: +1 212 253 8881
bberry@berrypr.com

MAUNA KEA TECHNOLOGIES's latest news

25/04/2024 20:50

MAUNA KEA TECHNOLOGIES (EPA:MKEA) Mauna Kea Technologies: Grenoble University Hospital first hospital in France to set up a multidisciplinary optical biopsy program with the Cellvizio endomicroscopy platform

Transparency directive : regulatory news

MAUNA KEA TECHNOLOGIES's latest news

Other stories